0 XP   0   0   0

Fagron NV
Buy, Hold or Sell?

Should you buy, hold or sell Fagron?

I guess you are interested in Fagron NV. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Fagron

Let's start. I'm going to help you getting a better view of Fagron NV. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Fagron NV even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Fagron NV is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Fagron NV. The closing price on 2023-03-20 was €15.22 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Fagron NV Daily Candlestick Chart
Fagron NV Daily Candlestick Chart
Summary









1. Valuation of Fagron




Current price per share

€15.22

2. Growth of Fagron




Is Fagron growing?

Current yearPrevious yearGrowGrow %
How rich?$352.6m$279.3m$73.2m20.8%

How much money is Fagron making?

Current yearPrevious yearGrowGrow %
Making money$66m$64.5m$1.5m2.3%
Net Profit Margin10.6%10.7%--

How much money comes from the company's main activities?

3. Financial Health of Fagron




Comparing to competitors in the Drug Manufacturers-Specialty & Generic industry




  Industry Rankings (Drug Manufacturers-Specialty & Generic)  


Richest
#200 / 695

Most Revenue
#48 / 695

Most Profit
#56 / 695

Most Efficient
#177 / 695


Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

1.1. Profitability of Fagron NV.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Fagron earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Fagron to the Drug Manufacturers-Specialty & Generic industry mean.
  • A Net Profit Margin of 10.6% means that €0.11 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Fagron NV:

  • The MRQ is 10.6%. The company is making a huge profit. +2
  • The TTM is 10.6%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ10.6%TTM10.6%0.0%
TTM10.6%YOY10.7%-0.1%
TTM10.6%5Y9.7%+0.9%
5Y9.7%10Y0.4%+9.3%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ10.6%1.4%+9.2%
TTM10.6%0.2%+10.4%
YOY10.7%1.8%+8.9%
5Y9.7%-0.1%+9.8%
10Y0.4%0.3%+0.1%
1.1.2. Return on Assets

Shows how efficient Fagron is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Fagron to the Drug Manufacturers-Specialty & Generic industry mean.
  • 7.6% Return on Assets means that Fagron generated €0.08 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Fagron NV:

  • The MRQ is 7.6%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 7.6%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ7.6%TTM7.6%0.0%
TTM7.6%YOY7.9%-0.3%
TTM7.6%5Y6.9%+0.7%
5Y6.9%10Y0.7%+6.3%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ7.6%-0.2%+7.8%
TTM7.6%-0.4%+8.0%
YOY7.9%-0.1%+8.0%
5Y6.9%-0.3%+7.2%
10Y0.7%-0.1%+0.8%
1.1.3. Return on Equity

Shows how efficient Fagron is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Fagron to the Drug Manufacturers-Specialty & Generic industry mean.
  • 19.1% Return on Equity means Fagron generated €0.19 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Fagron NV:

  • The MRQ is 19.1%. Using its investors money, the company is efficient in making profit. +1
  • The TTM is 19.1%. Using its investors money, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ19.1%TTM19.1%0.0%
TTM19.1%YOY23.5%-4.5%
TTM19.1%5Y21.2%-2.1%
5Y21.2%10Y10.0%+11.2%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ19.1%0.5%+18.6%
TTM19.1%0.2%+18.9%
YOY23.5%0.6%+22.9%
5Y21.2%-0.5%+21.7%
10Y10.0%-0.3%+10.3%

1.2. Operating Efficiency of Fagron NV.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Fagron is operating .

  • Measures how much profit Fagron makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Fagron to the Drug Manufacturers-Specialty & Generic industry mean.
  • An Operating Margin of 14.7% means the company generated €0.15  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Fagron NV:

  • The MRQ is 14.7%. The company is operating less efficient.
  • The TTM is 14.7%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ14.7%TTM14.7%0.0%
TTM14.7%YOY15.1%-0.4%
TTM14.7%5Y14.6%+0.1%
5Y14.6%10Y6.4%+8.2%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ14.7%3.4%+11.3%
TTM14.7%3.4%+11.3%
YOY15.1%4.3%+10.8%
5Y14.6%2.7%+11.9%
10Y6.4%1.8%+4.6%
1.2.2. Operating Ratio

Measures how efficient Fagron is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers-Specialty & Generic industry mean).
  • An Operation Ratio of 0.84 means that the operating costs are €0.84 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Fagron NV:

  • The MRQ is 0.843. The company is less efficient in keeping operating costs low.
  • The TTM is 0.843. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.843TTM0.8430.000
TTM0.843YOY0.834+0.009
TTM0.8435Y0.835+0.008
5Y0.83510Y0.832+0.003
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8431.419-0.576
TTM0.8431.446-0.603
YOY0.8341.409-0.575
5Y0.8351.410-0.575
10Y0.8321.224-0.392

1.3. Liquidity of Fagron NV.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Fagron is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers-Specialty & Generic industry mean).
  • A Current Ratio of 1.61 means the company has €1.61 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Fagron NV:

  • The MRQ is 1.611. The company is able to pay all its short-term debts. +1
  • The TTM is 1.611. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.611TTM1.6110.000
TTM1.611YOY1.108+0.503
TTM1.6115Y1.313+0.298
5Y1.31310Y1.116+0.197
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6111.856-0.245
TTM1.6111.980-0.369
YOY1.1082.228-1.120
5Y1.3132.327-1.014
10Y1.1162.060-0.944
1.3.2. Quick Ratio

Measures if Fagron is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Fagron to the Drug Manufacturers-Specialty & Generic industry mean.
  • A Quick Ratio of 0.98 means the company can pay off €0.98 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Fagron NV:

  • The MRQ is 0.985. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.985. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.985TTM0.9850.000
TTM0.985YOY0.710+0.275
TTM0.9855Y0.832+0.153
5Y0.83210Y0.654+0.178
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9850.817+0.168
TTM0.9850.892+0.093
YOY0.7100.928-0.218
5Y0.8321.023-0.191
10Y0.6541.000-0.346

1.4. Solvency of Fagron NV.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Fagron assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Fagron to Drug Manufacturers-Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.59 means that Fagron assets are financed with 59.3% credit (debt) and the remaining percentage (100% - 59.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Fagron NV:

  • The MRQ is 0.593. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.593. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.593TTM0.5930.000
TTM0.593YOY0.658-0.064
TTM0.5935Y0.665-0.072
5Y0.66510Y0.756-0.091
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5930.430+0.163
TTM0.5930.421+0.172
YOY0.6580.401+0.257
5Y0.6650.411+0.254
10Y0.7560.414+0.342
1.4.2. Debt to Equity Ratio

Measures if Fagron is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Fagron to the Drug Manufacturers-Specialty & Generic industry mean.
  • A Debt to Equity ratio of 148.4% means that company has €1.48 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Fagron NV:

  • The MRQ is 1.484. The company is able to pay all its debts with equity. +1
  • The TTM is 1.484. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.484TTM1.4840.000
TTM1.484YOY1.956-0.472
TTM1.4845Y2.057-0.573
5Y2.05710Y2.671-0.614
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4840.674+0.810
TTM1.4840.684+0.800
YOY1.9560.629+1.327
5Y2.0570.694+1.363
10Y2.6710.708+1.963

2. Market Valuation of Fagron NV

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Fagron generates.

  • Above 15 is considered overpriced but always compare Fagron to the Drug Manufacturers-Specialty & Generic industry mean.
  • A PE ratio of 17.68 means the investor is paying €17.68 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Fagron NV:

  • The EOD is 18.185. Very good. +2
  • The MRQ is 17.683. Very good. +2
  • The TTM is 17.683. Very good. +2
Trends
Current periodCompared to+/- 
EOD18.185MRQ17.683+0.502
MRQ17.683TTM17.6830.000
TTM17.683YOY23.236-5.553
TTM17.6835Y23.525-5.841
5Y23.52510Y19.959+3.566
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
EOD18.185-0.036+18.221
MRQ17.683-0.098+17.781
TTM17.6830.506+17.177
YOY23.2365.667+17.569
5Y23.5254.869+18.656
10Y19.95913.768+6.191
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Fagron.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Fagron NV:

  • The MRQ is 17.277. Seems overpriced? -1
  • The TTM is 17.277. Seems overpriced? -1
Trends
Current periodCompared to+/- 
MRQ17.277TTM17.2770.000
TTM17.277YOY15.980+1.296
TTM17.2775Y19.993-2.716
5Y19.99310Y24.661-4.668
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ17.2776.868+10.409
TTM17.27716.059+1.218
YOY15.98016.740-0.760
5Y19.99342.292-22.299
10Y24.66165.513-40.852

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Fagron is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers-Specialty & Generic industry mean).
  • A PB ratio of 3.31 means the investor is paying €3.31 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Fagron NV:

  • The EOD is 3.409. Neutral. Compare to industry.
  • The MRQ is 3.315. Neutral. Compare to industry.
  • The TTM is 3.315. Neutral. Compare to industry.
Trends
Current periodCompared to+/- 
EOD3.409MRQ3.315+0.094
MRQ3.315TTM3.3150.000
TTM3.315YOY5.372-2.057
TTM3.3155Y4.775-1.461
5Y4.77510Y5.428-0.652
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
EOD3.4091.394+2.015
MRQ3.3151.532+1.783
TTM3.3151.801+1.514
YOY5.3722.256+3.116
5Y4.7752.422+2.353
10Y5.4283.099+2.329
2. Total Gains per Share

2.4. Latest News of Fagron NV

Does Fagron NV still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Fagron NV to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2023-03-20
08:00
Fagron publishes annual report 2022Read

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Fagron NV compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.9280.9280%0.162+475%0.474+96%0.144+544%
Book Value Growth--1.2621.2620%1.046+21%1.165+8%1.253+1%
Book Value Per Share--4.4654.4650%3.537+26%3.358+33%2.565+74%
Book Value Per Share Growth--1.2621.2620%1.048+20%1.165+8%1.253+1%
Current Ratio--1.6111.6110%1.108+45%1.313+23%1.116+44%
Debt To Asset Ratio--0.5930.5930%0.658-10%0.665-11%0.756-22%
Debt To Equity Ratio--1.4841.4840%1.956-24%2.057-28%2.671-44%
Dividend Per Share--0.1790.1790%0.079+126%0.115+56%0.187-5%
Dividend Per Share Growth--2.2592.2590%0.671+237%1.226+84%1.134+99%
Eps--0.8370.8370%0.818+2%0.688+22%0.077+992%
Eps Growth--1.0241.0240%1.454-30%1.724-41%0.139+639%
Free Cash Flow Per Share--0.7910.7910%1.023-23%0.875-10%0.822-4%
Free Cash Flow Per Share Growth--0.7740.7740%1.357-43%1.054-27%1.029-25%
Free Cash Flow To Equity Per Share---0.054-0.0540%0.294-118%-0.282+420%0.608-109%
Free Cash Flow To Equity Per Share Growth---0.185-0.1850%0.425-144%0.464-140%2.996-106%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--9.207--------
Intrinsic Value_10Y_min--3.849--------
Intrinsic Value_1Y_max--0.872--------
Intrinsic Value_1Y_min--0.696--------
Intrinsic Value_3Y_max--2.659--------
Intrinsic Value_3Y_min--1.835--------
Intrinsic Value_5Y_max--4.492--------
Intrinsic Value_5Y_min--2.685--------
Net Profit Margin--0.1060.1060%0.107-1%0.097+9%0.004+2312%
Operating Margin--0.1470.1470%0.151-3%0.146+1%0.064+130%
Operating Ratio--0.8430.8430%0.834+1%0.835+1%0.832+1%
Pb Ratio3.409+3%3.3153.3150%5.372-38%4.775-31%5.428-39%
Pe Ratio18.185+3%17.68317.6830%23.236-24%23.525-25%19.959-11%
Peg Ratio--17.27717.2770%15.980+8%19.993-14%24.661-30%
Price Per Share15.220+3%14.80014.8000%19.000-22%15.765-6%17.346-15%
Price To Total Gains Ratio13.751+3%13.37113.3710%78.961-83%35.489-62%28.334-53%
Profit Growth--1.0241.0240%1.452-29%1.724-41%0.138+639%
Quick Ratio--0.9850.9850%0.710+39%0.832+18%0.654+51%
Return On Assets--0.0760.0760%0.079-4%0.069+10%0.007+1062%
Return On Equity--0.1910.1910%0.235-19%0.212-10%0.100+91%
Revenue Growth--1.0321.0320%1.040-1%1.064-3%1.025+1%
Total Gains Per Share--1.1071.1070%0.241+360%0.588+88%0.331+234%
Total Gains Per Share Growth--4.6004.6000%0.390+1078%1.477+211%0.476+866%
Usd Book Value--352609864.400352609864.4000%279318937.800+26%265286090.960+33%202586699.440+74%
Usd Book Value Change Per Share--1.0061.0060%0.175+475%0.513+96%0.156+544%
Usd Book Value Per Share--4.8384.8380%3.832+26%3.638+33%2.779+74%
Usd Dividend Per Share--0.1940.1940%0.086+126%0.124+56%0.203-5%
Usd Eps--0.9070.9070%0.886+2%0.745+22%0.083+992%
Usd Free Cash Flow--62499179.20062499179.2000%80747968.800-23%69125253.600-10%64956980.440-4%
Usd Free Cash Flow Per Share--0.8570.8570%1.108-23%0.948-10%0.891-4%
Usd Free Cash Flow To Equity Per Share---0.059-0.0590%0.318-118%-0.306+420%0.658-109%
Usd Price Per Share16.489+3%16.03416.0340%20.585-22%17.080-6%18.792-15%
Usd Profit--66091733.60066091733.6000%64571723.400+2%54344427.400+22%6061081.300+990%
Usd Revenue--621663587.200621663587.2000%602338981.400+3%557536491.160+12%525244995.780+18%
Usd Total Gains Per Share--1.1991.1990%0.261+360%0.637+88%0.359+234%
 EOD+2 -3MRQTTM+0 -0YOY+24 -185Y+30 -1210Y+30 -12

3.2. Fundamental Score

Let's check the fundamental score of Fagron NV based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1518.185
Price to Book Ratio (EOD)Between0-13.409
Net Profit Margin (MRQ)Greater than00.106
Operating Margin (MRQ)Greater than00.147
Quick Ratio (MRQ)Greater than10.985
Current Ratio (MRQ)Greater than11.611
Debt to Asset Ratio (MRQ)Less than10.593
Debt to Equity Ratio (MRQ)Less than11.484
Return on Equity (MRQ)Greater than0.150.191
Return on Assets (MRQ)Greater than0.050.076
Total6/10 (60.0%)

3.3. Technical Score

Let's check the technical score of Fagron NV based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5057.233
Ma 20Greater thanMa 5015.015
Ma 50Greater thanMa 10014.406
Ma 100Greater thanMa 20013.566
OpenGreater thanClose15.100
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2017-12-312018-12-312019-12-312020-12-312021-12-31
Minority Interest  3,4833923,8755384,4132994,712-5,087-375



Latest Balance Sheet

Balance Sheet of 2021-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets800,421
Total Liabilities474,955
Total Stockholder Equity320,105
 As reported
Total Liabilities 474,955
Total Stockholder Equity+ 320,105
Total Assets = 800,421

Assets

Total Assets800,421
Total Current Assets233,711
Long-term Assets233,711
Total Current Assets
Cash And Cash Equivalents 70,647
Net Receivables 72,232
Inventory 90,834
Total Current Assets  (as reported)233,711
Total Current Assets  (calculated)233,713
+/- 2
Long-term Assets
Property Plant Equipment 128,626
Goodwill 380,410
Intangible Assets 30,666
Other Assets 31,346
Long-term Assets  (as reported)566,710
Long-term Assets  (calculated)571,048
+/- 4,338

Liabilities & Shareholders' Equity

Total Current Liabilities145,062
Long-term Liabilities329,893
Total Stockholder Equity320,105
Total Current Liabilities
Short-term Debt 14,318
Short Long Term Debt 6,796
Accounts payable 83,660
Other Current Liabilities 31,821
Total Current Liabilities  (as reported)145,062
Total Current Liabilities  (calculated)136,595
+/- 8,467
Long-term Liabilities
Long term Debt Total 321,270
Other Liabilities 8,623
Deferred Long Term Liability 7,090
Long-term Liabilities  (as reported)329,893
Long-term Liabilities  (calculated)336,983
+/- 7,090
Total Stockholder Equity
Common Stock520,785
Retained Earnings 95,297
Other Stockholders Equity -295,977
Total Stockholder Equity (as reported)320,105
Total Stockholder Equity (calculated)320,105
+/-0
Other
Capital Stock520,785
Cash And Equivalents394
Cash and Short Term Investments 70,647
Common Stock Shares Outstanding 72,715
Liabilities and Stockholders Equity 795,060
Net Debt 264,941
Net Invested Capital 617,487
Net Tangible Assets -83,881
Net Working Capital 88,649
Short Long Term Debt Total 335,588



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-31
> Total Assets 
273,194
272,038
285,458
347,467
417,733
472,160
573,592
680,232
748,895
804,693
973,751
689,382
868,052
594,047
682,775
801,238
752,824
800,421
800,421752,824801,238682,775594,047868,052689,382973,751804,693748,895680,232573,592472,160417,733347,467285,458272,038273,194
   > Total Current Assets 
120,847
112,232
112,446
156,096
163,518
182,628
217,782
233,856
237,607
236,536
228,114
187,846
412,346
166,430
199,726
239,189
221,883
233,711
233,711221,883239,189199,726166,430412,346187,846228,114236,536237,607233,856217,782182,628163,518156,096112,446112,232120,847
       Cash And Cash Equivalents 
5,072
4,707
2,532
27,789
18,503
34,284
51,186
69,850
72,353
128,871
108,552
75,474
74,962
60,771
77,579
106,684
84,248
70,647
70,64784,248106,68477,57960,77174,96275,474108,552128,87172,35369,85051,18634,28418,50327,7892,5324,7075,072
       Net Receivables 
0
0
0
0
0
0
0
0
0
48,748
54,380
45,121
56,708
42,794
47,489
55,026
57,842
72,232
72,23257,84255,02647,48942,79456,70845,12154,38048,748000000000
       Inventory 
56,020
51,438
50,062
56,521
62,808
60,771
66,059
76,643
85,963
58,917
65,181
67,251
60,054
62,865
74,658
77,479
79,794
90,834
90,83479,79477,47974,65862,86560,05467,25165,18158,91785,96376,64366,05960,77162,80856,52150,06251,43856,020
       Other Current Assets 
59,755
56,087
59,852
71,786
82,207
87,573
100,537
87,363
79,291
48,748
54,381
45,121
277,330
42,794
47,489
55,026
57,841
72,230
72,23057,84155,02647,48942,794277,33045,12154,38148,74879,29187,363100,53787,57382,20771,78659,85256,08759,755
   > Long-term Assets 
152,347
159,806
173,012
191,371
254,215
289,532
355,810
446,376
511,288
568,157
745,637
501,536
455,706
427,617
483,049
562,049
530,941
566,710
566,710530,941562,049483,049427,617455,706501,536745,637568,157511,288446,376355,810289,532254,215191,371173,012159,806152,347
       Property Plant Equipment 
16,287
16,844
16,397
21,195
34,473
38,631
48,862
57,150
59,256
47,455
59,968
71,133
72,878
69,535
73,440
121,207
118,624
128,626
128,626118,624121,20773,44069,53572,87871,13359,96847,45559,25657,15048,86238,63134,47321,19516,39716,84416,287
       Goodwill 
0
0
0
0
0
0
0
0
382,481
371,630
522,069
373,608
297,785
322,838
365,136
389,326
364,654
380,410
380,410364,654389,326365,136322,838297,785373,608522,069371,630382,48100000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
867
1,595
1,540
1,270
1,214
943
4,287
0
0
004,2879431,2141,2701,5401,595867000000000
       Intangible Assets 
0
0
0
155,662
201,126
229,455
284,498
367,069
35,385
28,956
53,184
36,994
73,221
21,657
26,253
28,810
24,512
30,666
30,66624,51228,81026,25321,65773,22136,99453,18428,95635,385367,069284,498229,455201,126155,662000
       Long-term Assets Other 
2,875
2,822
922
897
2,018
2,241
1,665
1,789
1,870
91,824
88,053
5,859
2,124
2,232
2,159
4,286
2,340
4,463
4,4632,3404,2862,1592,2322,1245,85988,05391,8241,8701,7891,6652,2412,0188979222,8222,875
> Total Liabilities 
170,654
189,171
190,576
169,242
232,203
275,808
365,470
459,780
503,510
649,526
816,809
754,155
715,179
409,166
473,056
554,799
495,007
474,955
474,955495,007554,799473,056409,166715,179754,155816,809649,526503,510459,780365,470275,808232,203169,242190,576189,171170,654
   > Total Current Liabilities 
143,458
174,019
132,419
157,072
100,955
118,711
139,723
447,045
188,371
230,364
220,938
727,090
406,053
108,241
187,806
191,771
200,256
145,062
145,062200,256191,771187,806108,241406,053727,090220,938230,364188,371447,045139,723118,711100,955157,072132,419174,019143,458
       Short-term Debt 
75,855
100,160
53,618
72,917
0
4,876
2,315
1,935
4,865
55,004
5,710
594,908
290,559
13,451
63,955
40,723
71,090
14,318
14,31871,09040,72363,95513,451290,559594,9085,71055,0044,8651,9352,3154,876072,91753,618100,16075,855
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
426,165
5,349
596,666
290,475
13,386
63,889
34,119
64,440
6,796
6,79664,44034,11963,88913,386290,475596,6665,349426,165000000000
       Accounts payable 
46,159
49,058
49,525
56,943
64,624
67,605
80,845
94,194
97,641
55,551
57,440
63,043
53,163
58,950
63,918
77,303
72,252
83,660
83,66072,25277,30363,91858,95053,16363,04357,44055,55197,64194,19480,84567,60564,62456,94349,52549,05846,159
       Other Current Liabilities 
21,444
24,801
29,276
27,212
36,331
46,230
56,563
350,916
85,865
119,809
157,788
69,139
62,331
35,840
42,061
55,028
25,341
31,821
31,82125,34155,02842,06135,84062,33169,139157,788119,80985,865350,91656,56346,23036,33127,21229,27624,80121,444
   > Long-term Liabilities 
27,196
15,152
58,157
12,170
131,248
157,097
225,747
12,735
315,139
419,162
595,871
27,065
309,126
300,925
285,250
363,028
294,751
329,893
329,893294,751363,028285,250300,925309,12627,065595,871419,162315,13912,735225,747157,097131,24812,17058,15715,15227,196
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
290,433
283,518
265,917
350,808
284,448
321,270
321,270284,448350,808265,917283,518290,433000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
17,936
21,107
22,653
18,692
17,407
19,201
11,769
10,303
8,623
8,62310,30311,76919,20117,40718,69222,65321,10717,936000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
23,108
2,996
2,301
3,797
3,870
5,132
6,265
6,205
7,090
7,0906,2056,2655,1323,8703,7972,3012,99623,108000000000
> Total Stockholder Equity
102,540
82,867
94,882
178,225
181,562
194,306
205,838
216,672
241,631
151,552
154,626
-67,474
149,791
181,398
205,841
242,028
253,107
320,105
320,105253,107242,028205,841181,398149,791-67,474154,626151,552241,631216,672205,838194,306181,562178,22594,88282,867102,540
   Common Stock
0
0
0
0
0
0
0
317,527
318,134
318,927
319,660
345,760
561,852
507,670
507,670
510,142
513,987
520,785
520,785513,987510,142507,670507,670561,852345,760319,660318,927318,134317,5270000000
   Retained Earnings 
0
0
0
0
0
0
0
107,232
135,910
84,966
78,983
-154,501
-175,063
-74,223
-38,921
-6,486
47,340
95,297
95,29747,340-6,486-38,921-74,223-175,063-154,50178,98384,966135,910107,2320000000
   Capital Surplus 000000000000000000
   Treasury Stock000000000000000000
   Other Stockholders Equity -295,977-225,346-186,475-190,363-191,269-174,191-200,126-196,040-211,256-168,356-166,5010000000



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue573,808
Cost of Revenue-326,312
Gross Profit247,496247,496
 
Operating Income (+$)
Gross Profit247,496
Operating Expense-157,574
Operating Income87,43889,922
 
Operating Expense (+$)
Research Development-
Selling General Administrative134,586
Selling And Marketing Expenses-
Operating Expense157,574134,586
 
Net Interest Income (+$)
Interest Income1,421
Interest Expense-8,006
Net Interest Income-11,279-6,585
 
Pretax Income (+$)
Operating Income87,438
Net Interest Income-11,279
Other Non-Operating Income Expenses-
Income Before Tax (EBT)76,82098,056
EBIT - interestExpense = 76,446
76,446
69,010
Interest Expense8,006
Earnings Before Interest and Taxes (ebit)84,45284,826
Earnings Before Interest and Taxes (ebitda)110,935
 
After tax Income (+$)
Income Before Tax76,820
Tax Provision-15,442
Net Income From Continuing Ops61,37861,378
Net Income61,004
Net Income Applicable To Common Shares61,004
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses483,886
Total Other Income/Expenses Net-10,61811,279
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
AAGH.PINK
29 minutes ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of AAGH.PINK.

AAGH.PINK Daily Candlestick Chart
WSNAF.OTCQB
33 minutes ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of WSNAF.OTCQB.

WSNAF.OTCQB Daily Candlestick Chart
XINT.ST
1 hour ago

I found you a Bearish Three Line Strike Candle Pattern on the daily chart of XINT.ST.

XINT.ST Daily Candlestick Chart
ELAN.NYSE
1 hour ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of ELAN.NYSE.

ELAN.NYSE Daily Candlestick Chart
EIGR.NASDAQ
1 hour ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of EIGR.NASDAQ.

EIGR.NASDAQ Daily Candlestick Chart
EFSC.NASDAQ
1 hour ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of EFSC.NASDAQ.

EFSC.NASDAQ Daily Candlestick Chart
DZZ.NYSE ARC
1 hour ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of DZZ.NYSE ARC.

DZZ.NYSE ARC Daily Candlestick Chart
CANS.V
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CANS.V.

CANS.V Daily Candlestick Chart
DRMA.NASDAQ
1 hour ago

I found you a RSI Bullish Hidden Divergence on the daily chart of DRMA.NASDAQ.

DRMA.NASDAQ Daily Candlestick Chart
DRFS.PINK
1 hour ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of DRFS.PINK.

DRFS.PINK Daily Candlestick Chart
DISH.NASDAQ
2 hours ago

I found you a STOCH Bearish Hidden Divergence on the daily chart of DISH.NASDAQ.

DISH.NASDAQ Daily Candlestick Chart
EDGE.TO
2 hours ago

I found you a Golden Cross on the daily chart of EDGE.TO.

EDGE.TO Daily Candlestick Chart
ENRG.V
2 hours ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of ENRG.V.

ENRG.V Daily Candlestick Chart
EFR.TO
2 hours ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of EFR.TO.

EFR.TO Daily Candlestick Chart
DML.TO
2 hours ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of DML.TO.

DML.TO Daily Candlestick Chart
DOO.TO
2 hours ago

I found you a Bullish Three Line Strike Candle Pattern on the daily chart of DOO.TO.

DOO.TO Daily Candlestick Chart
CIX.TO
2 hours ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of CIX.TO.

CIX.TO Daily Candlestick Chart
BYL.TO
2 hours ago

I found you a STOCH Bearish Hidden Divergence on the daily chart of BYL.TO.

BYL.TO Daily Candlestick Chart
3LLV.PA
2 hours ago

I found you a MACD Bearish Reversal Divergence on the daily chart of 3LLV.PA.

3LLV.PA Daily Candlestick Chart
MAC.LSE
3 hours ago

I found you a STOCH Bearish Hidden Divergence on the daily chart of MAC.LSE.

MAC.LSE Daily Candlestick Chart
KCT.LSE
3 hours ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of KCT.LSE.

KCT.LSE Daily Candlestick Chart
S5FI.INDX
4 hours ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of S5FI.INDX.

S5FI.INDX Daily Candlestick Chart
MMFI.INDX
4 hours ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of MMFI.INDX.

MMFI.INDX Daily Candlestick Chart
STU.V
4 hours ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of STU.V.

STU.V Daily Candlestick Chart